Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Obesity-related CLIA Kit

Inquiry

CLIA Kit - Multiple Options for Your Obesity Research

(Protheragen)

For an extended period, Protheragen has dedicated itself to the critical domain of obesity research, providing a comprehensive portfolio of chemiluminescent Immunoassay (CLIA) kits to advance this field. These meticulously crafted CLIA kits empower researchers to precisely quantify pivotal biomarkers correlated with obesity across diverse biological matrices. Employing state-of-the-art chemiluminescence technology, they offer a robust and streamlined solution for conducting thorough investigations into the multifaceted aspects of obesity, including its underlying pathophysiology, accurate diagnosis, effective therapeutic interventions, and the development of novel pharmaceutical agents.

Detection Principle of CLIA

Chemiluminescent Immunoassay (CLIA) delicately combines the sensitivity of chemiluminescence with the specificity of immunoassay, resulting in high accuracy and a wide detection range. During the immunoassay process, antibodies or antigens are directly labeled with chemicals or enzymes. When the labeled antibody or antigen reacts with the target analyte, an immunoreactive complex is formed. Subsequently, a chemiluminescent substrate is added depending on the specific conditions of the immunoreaction. This substrate is converted to an excited state intermediate by oxidation and releases photons to reach a steady state. By measuring the intensity of the chemiluminescence with a luminescence signal meter, the amount of the substance to be measured is precisely determined.

CLIA testing principle. (Protheragen)

Applications

  • The molecular mechanisms analysis of obesity: These CLIA kits can help researchers quantify key biomarkers associated with obesity, providing insight into the molecular mechanisms of obesity.
  • Screening potential therapeutic targets: By detecting changes in various biomarkers, researchers can better understand the mechanism of action of obesity and identify new potential therapeutic targets.
  • Evaluating drug efficacy: During drug development, these CLIA kits are used to evaluate the effects of obesity-related biomarkers to monitor the therapeutic effects of potential anti-obesity drugs and their absorption, distribution, metabolism, and excretion processes in the body.

Advantages of Our CLIA Kits

  • High sensitivity and specificity: These kits use high-quality antibodies and optimized detection protocols to ensure precise and sensitive quantitative analysis of the target biomarkers, reduce cross-reactivity, and improve detection accuracy.
  • Wide range of applications: Our kits are capable of detecting different concentrations of target analytes and are suitable for analyzing a wide range of research samples.
  • Multiple target analyte selection: CLIA kits target a variety of key biomarkers associated with obesity.
  • Research-grade quality: Our CLIA kits are designed for scientific research, providing reliable data to support your research breakthroughs.

Publication

The study scrutinizes the relationship between inflammatory markers, leptin receptor gene diversity, and childhood obesity. The researchers measured serum interleukin-1β levels using the CLIA method, analyzed single-nucleotide polymorphisms in the leptin receptor gene by next-generation sequencing (NGS), and also examined levels of lipocalin, leptin, interleukin-6, and C-reactive protein. It was found that single-nucleotide polymorphisms in the leptin receptor gene were associated with metabolically unhealthy obesity.

Tab.1 Mean concentration (M ± m) and median (Me)* of serum inflammatory markers values. (Abaturov & Nikulina, 2021)

Indicator, units Reference values Patients with MUO (n = 56) Patients with MUO (n = 53) P
M ± m Me M ± m Me
IL-1β, pg/mL 0 - 5 2.5 ± 0.3 1.9 1.8 ± 0.7 1.7 >0.05
IL-6, pg/mL 1.5 - 7.0 7.4 ± 0.5 6.8 4.3 ± 0.3 3.4 <0.05
C-reactive protein, mg/L 0 - 5 2.6 ± 0.7 2.3 2.1 ± 0.4 2 >0.05
Leptin, ng/mL
Boys
Girls
2.0 - 5.6 29.3 ± 8.9 25 26.0 ± 6.4 24.4 >0.05
3.7 - 11.1 47.8 ± 4.4 45.2 32.5 ± 4.3 28.5 <0.05
Adiponectin, μg/mL ≥10 3.9 ± 0.8 3.1 7.7 ± 2.4 6.5 <0.05

*: Me with 95 % CI median

These data not only provide a solid foundation for obesity research but also indirectly highlight the positive role of CLIA kits in promoting accurate obesity diagnosis and research.

Frequently Asked Questions

  1. What targets do obesity-related CLIA kits detect?

    These CLIA kits typically detect a variety of biomarkers associated with obesity and its complications, including but not limited to:

    • Hormones related to appetite and metabolism include leptin, lipocalin, insulin, gastrin, etc.
    • Indicators of inflammation: e.g., C-reactive protein (CRP)
    • Other related markers
  2. What types of samples are these CLIA kits used for?
    • Blood samples
    • Tissue homogenates
    • Cell lysates
    • Cell culture supernatants
    • Other biological fluids

As a valuable detection tool, the CLIA kit adopts advanced chemiluminescence immunoassay technology, which accurately and rapidly detects various biomarkers, providing powerful data support for researchers and helping in-depth studies of various diseases. Protheragen, as a company specializing in the research of obesity and related diseases, has rich R&D experience and strong technical capabilities. We offer a wide range of CLIA kits with multiple advantages, providing researchers with powerful research tools. Welcome to contact us for more detailed CLIA kit information.

Reference

  1. Abaturov, A.E.; Nikulina, A.O. Association of leptin receptor gene polymorphisms and meta-inflammation markers with metabolically unhealthy obesity in children. Zaporozhye Medical Journal. 2021, 23(5): 696-702. (CC BY 4.0)

CLIA Kits:

Assay Type
Target Species
Assay Target
Research Area
Human adrenocorticotropic hormone (ACTH) CLIA kit
  • Target Species: Human
  • Research Area: Hormone research; Circadian rhythm; Obesity
  • Detection Method:
Human adrenocorticotropic hormone (ACTH) CLIA kit
Mouse adrenocorticotropic hormone (ACTH) CLIA kit
  • Target Species: Mouse
  • Research Area: Hormone research; Circadian rhythm; Obesity
  • Detection Method:
Mouse adrenocorticotropic hormone (ACTH) CLIA kit
Rat adrenocorticotropic hormone (ACTH) CLIA kit
  • Target Species: Rat
  • Research Area: Hormone research; Circadian rhythm; Obesity
  • Detection Method:
Rat adrenocorticotropic hormone (ACTH) CLIA kit
Human adiponectin (ADP) CLIA kit
  • Target Species: Human
  • Research Area: Hormone research; Lipid metabolism; Obesity
  • Detection Method:
Human adiponectin (ADP) CLIA kit
Mouse adiponectin (ADP) CLIA kit
  • Target Species: Mouse
  • Research Area: Hormone research; Lipid metabolism; Obesity
  • Detection Method:
Mouse adiponectin (ADP) CLIA kit
Chicken adiponectin (ADPN) CLIA kit
  • Target Species: Chicken
  • Research Area: Hormone research; Lipid metabolism; Obesity
  • Detection Method:
Chicken adiponectin (ADPN) CLIA kit
Human C reactive protein (CRP) CLIA kit
  • Target Species: Human
  • Research Area: Inflammation; Obesity
  • Detection Method:
Human C reactive protein (CRP) CLIA kit
Rat C reactive protein (CRP) CLIA kit
  • Target Species: Rat
  • Research Area: Inflammation; Obesity
  • Detection Method:
Rat C reactive protein (CRP) CLIA kit
Chicken fatty acid synthase (FASN) CLIA kit
  • Target Species: Chicken
  • Research Area: Fatty acid synthesis; Metabolic research; Obesity
  • Detection Method:
Chicken fatty acid synthase (FASN) CLIA kit
Rat fibroblast growth factor 21 (FGF21) CLIA kit
  • Target Species: Rat
  • Research Area: Hormone research; Metabolic research; Cytokine research; Obesity
  • Detection Method:
Rat fibroblast growth factor 21 (FGF21) CLIA kit
Inquiry

Copyright © Protheragen. All rights reserves.